BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30845975)

  • 1. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
    Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
    J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms.
    Zhou L; Zhang Y; Meads MB; Dai Y; Ning Y; Hu X; Li L; Sharma K; Nkwocha J; Parker R; Bui D; McCarter J; Kramer L; Purcell C; Sudalagunta PR; Canevarolo RR; Coelho Siqueira Silva MD; De Avila G; Alugubelli RR; Silva AS; Kmeiciak M; Ferreira-Gonzalez A; Shain KH; Grant S
    Blood Adv; 2021 Oct; 5(19):3776-3788. PubMed ID: 34464977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
    Leng Y; Hu X; Li L; Nkwocha J; Satta T; Sharma K; Kmeiciak M; Zhou H; Zhang Z; Zhou L; Chen W; Grant S
    Hematol Oncol; 2022 Dec; 40(5):999-1008. PubMed ID: 35789025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
    Zou P; Kawada J; Pesnicak L; Cohen JI
    J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.
    Eytan DF; Snow GE; Carlson S; Derakhshan A; Saleh A; Schiltz S; Cheng H; Mohan S; Cornelius S; Coupar J; Sowers AL; Hernandez L; Mitchell JB; Annunziata CM; Chen Z; Van Waes C
    Cancer Res; 2016 Sep; 76(18):5442-5454. PubMed ID: 27469115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
    Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J
    Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
    Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
    Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant.
    Fichtner M; Bozkurt E; Salvucci M; McCann C; McAllister KA; Halang L; Düssmann H; Kinsella S; Crawford N; Sessler T; Longley DB; Prehn JHM
    Cell Death Dis; 2020 Nov; 11(11):1020. PubMed ID: 33257690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells.
    Liu H; Liao R; He K; Zhu X; Li P; Gong J
    Immunol Lett; 2017 May; 185():79-83. PubMed ID: 28286228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
    Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
    Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
    Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
    J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
    Zhao Y; Zhang K; Li G; Zhang X; Shi D
    PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.